Clinical trials: Maculopathy, Age Related
Macular Degeneration
Complications of Age-Related Macular Degeneration Prevention Trial
To determine whether application of low-intensity laser treatment of eyes with drusen in the macula can prevent later complications of age-related macular degeneration and thereby preserve visual function.
- Trial name
- CAPT (NCT00000167)
- Testing
- Low-Intensity Laser Treatment
- Where
- 24 sites in United States
- Volunteers
- 1,052 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW1 (NCT00509795)
- Testing
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 188 sites in United States, Canada
- Volunteers
- 1,217 people
- Sponsor
- Regeneron Pharmaceuticals
Age Related Macular Degeneration
Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
This is a pilot study to evaluate the safety of the Model WA-NG telescope prosthesis in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.
- Trial name
- NCT01361256
- Testing
- Telescope prosthesis, WA-NG Telescope Prothesis
- Where
- Israel
- Sponsor
- VisionCare, Inc.
Age Related Macular Degeneration
Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.
- Trial name
- SHIFT-2 (NCT02002377)
- Testing
- Aflibercept
- Where
- 9 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Unity Health Toronto
Macular Degeneration, Age-Related Macular Degeneration
The Focal Electro-Oculogram in Macular Disease
Background: Maculopathies are eye conditions that affect the center of the retina. Retina health depends on the retinal pigment epithelium (RPE), a layer behind the retina.
- Trial name
- NCT02225119
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Eye Institute (NEI)
Age-related Macular Degeneration, Aging
Functionally Validated Structural Endpoints for Early AMD
Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD).
- Trial name
- ALSTAR2 (NCT04112667)
- Testing
- Normal Macular Health, Early Macular Degeneration, Young Normals
- Where
- United States
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Cynthia Owsley
Age-Related Macular Degeneration
OKKO Health Hyperacuity, Contrast and Colour Game Validation in Age-related Macular Degeneration
Smartphone apps have the potential to measure standard metrics of visual function. In addition, new tests may serve as digital biomarkers to detect early progression of disease, assess risk of developing disease or expand the…
- Trial name
- NCT05569226
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- OKKO Health
Macular Degeneration
Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
Wet age-related macular degeneration is the most common cause of blind registration in the United Kingdom (UK). Standard treatment involves regular eye injections of a drug called ranibizumab (Lucentis).
- Trial name
- MERLOT (NCT01006538)
- Testing
- Epimacular Brachytherapy, Ranibizumab
- Where
- 24 sites in United Kingdom
- Volunteers
- 363 people
- Sponsor
- King's College Hospital NHS Trust
Neovascular Age-related Macular Degeneration
A Study of EXG102-031 in Participants With wAMD
In neovascular (wet) age-related macular degeneration (wAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT06183814
- Testing
- EXG102-031
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Jiayin Biotech Ltd
Macular Degeneration, Geographic Atrophy
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).
- Trial name
- NCT03815825
- Testing
- IONIS-FB-LRx
- Where
- 88 sites in United States, Australia and 7 more
- Volunteers
- 332 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Age Related Macular Degeneration, Geographic Atrophy
Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)
The objective of this study is to compare Cirrus HD-OCT automated measurements of the illumination area under the retinal pigment epithelium (RPE) to expert manual measurements of areas of hypofluorescence typical of geographic…
- Trial name
- NCT01272076
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Carl Zeiss Meditec, Inc.
Age-related Macular Degeneration (ARMD)
Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities
Age-related macular degeneration (AMD) is one of the main causes of blindness in the elderly population. Intraocular injection of anti-VEGF drugs for neovascular AMD (nAMD) is the main treatment method at present.
- Trial name
- NCT06583109
- Volunteers
- 2,600 people
- Sponsor
- Beijing Hospital
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823287
- Testing
- Faricimab, Aflibercept
- Where
- 161 sites in United States, Canada and 13 more
- Volunteers
- 671 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD.
- Trial name
- NCT05986864
- Testing
- SKG0106
- Where
- 9 sites in United States, China
- Volunteers
- 68 people
- Sponsor
- Skyline Therapeutics (US) Inc.
Macular Degeneration
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.
- Trial name
- NCT01362348
- Testing
- pazopanib eye drops
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Macular Degeneration
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
The purpose of this study is to determine whether microplasmin given by intravitreal injection is effective and safe for the treatment of wet age-related macular degeneration (AMD) in patients who have focal vitreomacular…
- Trial name
- AMD (NCT00996684)
- Testing
- Microplasmin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Wet Age-related Macular Degeneration
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
" Wet Age-related Macular Degeneration (wet AMD)" is characterized by the appearance of new choroidal vessels. Several clinical studies have shown the effectiveness of intra-vitreous injections of anti-VEGF (bevacizumab…
- Trial name
- NCT04685369
- Testing
- Medical Data extraction
- Where
- Belgium
- Volunteers
- 148 people
- Sponsor
- Brugmann University Hospital
Age-related Macular Degeneration
Dose Ranging Study of Carbidopa-levodopa
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03023059
- Testing
- Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Diabetic Retinopathy, Macular Degeneration
Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)
Injections of medicine into the middle of the eye (intravitreal injections) are commonly used in a multitude of retinal diseases.
- Trial name
- ITVR (NCT00695682)
- Testing
- intravitreal injection of infliximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Retina Research Foundation
Exudative Age-Related Macular Degeneration
Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
This is a prospective study. Data from patients diagnosed with nAMD who have never received related treatment were collected. Treatment was an intravitreal injection of 0.5 mg conbercept using modified "T\&E" treatment plans.
- Trial name
- IIT-A (NCT05539235)
- Testing
- different degrees of adjustment of the injection interval
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University